News

Andy Lewis, Vice President, Pharmaceutical Sciences, has written an article for Drug Development & Delivery entitled, "Alternative Strategies for Development of Modified-Release Dosage Forms"

PharmaTech Outlook Interview with Kimberly Paris, SVP & Chief compliance officer at Quotient Sciences: "Addressing and Overcoming the Ever-evolving Challenges in development"

Richard Castledine talks to Pharmaceutical Technology about moving off the critical path and streamlining strategies for drug substance synthesis and manufacturing

Helen Baker, Director, Pharmaceutical Sci­ences at Quotient Sciences has recently been featured in Drug Development & Delivery's Special Feature: "Outsourcing Formulation Development & Manufacturing: Understanding Critical Attributes Earlier in Development Leads to a More Robust Drug Product"

Mark Egerton, CEO of Quotient Sciences was recently asked to contribute to a piece with Pharma's Almanac, entitled 'What’s the key to being a leader in the industry?'

Roundtable Interview with Paul Quigley, Principal Research Fellow, Drug Substance,& John McDermott, Executive Drug Development Consultant. Low-volume drugs, such as orphan drugs, present challenges in achieving favorable production economics and in managing the projects themselves. A roundtable of CDMOs provides perspectives on those challenges and best practices to resolve them.